#BEGIN_DRUGCARD DB01273

# AHFS_Codes:
Not Available

# ATC_Codes:
N07BA03

# Absorption:
Not Available

# Biotransformation:
Metabolism is limited (<10%). Most of the active compound is excreted renally (81%). A small proportion is glucuronidated, oxidated, N-formylated or conjugated to a hexose.

# Brand_Mixtures:
Not Available

# Brand_Names:
Champix
Chantix

# CAS_Registry_Number:
249296-44-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C13H13N3

# Chemical_IUPAC_Name:
(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene

# Chemical_Structure:
Not Available

# Creation_Date:
2007-05-16 14:24:49 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.

# Dosage_Forms:
Tablet, film coated	Oral

# Drug_Category:
Nicotinic Agonists

# Drug_Interactions:
Not Available

# Drug_Reference:
15887955	Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT: Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7.
16221753	Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW: Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006 Jan;34(1):121-30. Epub 2005 Oct 12.
16467225	Kuehn BM: FDA speeds smoking cessation drug review. JAMA. 2006 Feb 8;295(6):614.
16766716	Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.
16820547	Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.9

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Varenicline

# HET_ID:
Not Available

# Half_Life:
The elimination half-life of varenicline is approximately 24 hours

# InChI_Identifier:
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+

# InChI_Key:
InChIKey=JQSHBVHOMNKWFT-DTORHVGOSA-N

# Indication:
For use as an aid in smoking cessation.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1273

# Mechanism_Of_Action:
Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
211.2624

# Molecular_Weight_Mono:
211.110947431

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164781343

# Pharmacology:
Varenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.

# Predicted_LogP_Hydrophobicity:
1.39

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
8.77e-02 g/l

# Primary_Accession_No:
DB01273

# Protein_Binding:
Less than 20%.

# PubChem_Compound_ID:
5310966

# PubChem_Substance_ID:
46505502

# RxList_Link:
http://www.rxlist.com/cgi/generic/chantix.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CP-526,555
Varenicline tartrate

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:03 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Varenicline

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17573127	Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE: Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007 Jul;28(7):316-25. Epub 2007 Jun 18.
17626178	Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23. Epub 2007 Jul 11.
17692720	Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR: Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007 Jun;29(6):1040-56.
18288085	McColl S, Burstein A, Reeves K, Billing Jr C, Stolar M, Sellers E: Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers. Clin Pharmacol Ther. 2008 Feb 20;.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CHRNA4

# Drug_Target_1_GenBank_ID_Gene:
L35901

# Drug_Target_1_GenBank_ID_Protein:
755648

# Drug_Target_1_GeneCard_ID:
CHRNA4

# Drug_Target_1_Gene_Name:
CHRNA4

# Drug_Target_1_Gene_Sequence:
>1884 bp
ATGGAGCTAGGGGGCCCCGGAGCGCCGCGGCTGCTGCCGCCGCTGCTGCTGCTTCTGGGG
ACCGGCCTCCTGCGCGCCAGCAGCCATGTGGAGACCCGGGCCCACGCCGAGGAGCGGCTC
CTGAAGAAACTCTTCTCCGGTTACAACAAGTGGTCCCGACCCGTGGCCAACATCTCGGAC
GTGGTCCTCGTCCGCTTCGGCCTGTCCATCGCTCAGCTCATTGACGTGGATGAGAAGAAC
CAGATGATGACCACGAACGTATGGGTGAAGCAGGAGTGGCACGACTACAAGCTGCGCTGG
GACCCAGCTGACTATGAGAATGTCACCTCCATCCGCATCCCCTCCGAGCTCATCTGGCGG
CCGGACATCGTCCTCTACAACAATGCTGACGGGGACTTCGCGGTCACCCACCTGACCAAG
GCCCACCTGTTCCATGACGGGCGGGTGCAGTGGACTCCCCCGGCCATTTACAAGAGCTCC
TGCAGCATCGACGTCACCTTCTTCCCCTTCGACCAGCAGAACTGCACCATGAAATTCGGC
TCCTGGACCTACGACAAGGCCAAGATCGACCTGGTGAACATGCACAGCCGCGTGGACCAG
CTGGACTTCTGGGAGAGTGGCGAGTGGGTCATCGTGGATGCCGTGGGCACCTACAACACC
AGGAAGTACGAGTGCTGTGCCGAGATCTACCCGGACATCACCTATGCCTTCGTCATCCGG
CGGCTGCCGCTCTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTGCCTC
ACCGTGCTGGTCTTCTACCTGCCCTCCGAGTGTGGCGAGAAGATCACGCTGTGCATCTCC
GTGCTGCTGTCGCTCACCGTCTTCCTGCTGCTCATCACCGAGATCATCCCGTCCACCTCA
CTGGTCATCCCACTCATCGGCGAGTACCTGCTGTTCACCATGATCTTCGTCACCCTGTCC
ATCGTCATCACGGTCTTCGTGCTCAACGTGCACCACCGCTCGCCACGCACGCACACCATG
CCCACCTGGGTACGCAGGGTCTTCCTGGACATCGTGCCACGCCTGCTCCTCATGAAGCGG
CCGTCCGTGGTCAAGGACAATTGCCGGCGGCTCATCGAGTCCATGCATAAGATGGCCAGT
GCCCCGCGCTTCTGGCCCGAGCCAGAAGGGGAGCCCCCTGCCACGAGCGGCACCCAGAGC
CTGCACCCGCCCTCACCGTCCTTCTGTGTCCCCCTGGATGTGCCGGCTGAGCCTGGGCCT
TCCTGCAAGTCACCCTCCGACCAGCTCCCTCCTCAGCAGCCCCTGGAAGCTGAGAAAGCC
AGCCCCCACCCCTCGCCTGGACCCTGCCGCCCGCCCCACGGCACCCAGGCACCAGGGCTG
GCCAAAGCCAGGTCCCTCAGCGTCCAGCACATGTCCAGCCCTGGCGAAGCGGTGGAAGGC
GGCGTCCGGTGCCGGTCTCGGAGCATCCAGTACTGTGTTCCCCGAGACGATGCCGCCCCC
GAGGCAGATGGCCAGGCTGCCGGCGCCCTGGCCTCTCGCAACACCCACTCGGCTGAGCTC
CCACCCCCAGACCAGCCCTCTCCGTGCAAATGCACATGCAAGAAGGAGCCCTCTTCGGTG
TCCCCGAGTGCCACGGTCAAGACCCGCAGCACCAAAGCACCGCCCCCGCACCTGCCCCTG
TCGCCGGCCCTGACCCGGGCGGTGGAGGGCGTCCAGTACATTGCAGACCACCTGAAGGCC
GAAGACACAGACTTCTCGGTGAAGGAGGACTGGAAGTACGTGGCCATGGTCATCGACCGC
ATCTTCCTCTGGATGTTCATCATCGTCTGCCTGCTGGGGACGGTGGGCCTCTTCCTGCCG
CCCTGGCTGGCTGGCATGATCTAG

# Drug_Target_1_General_Function:
Involved in neurotransmitter receptor activity

# Drug_Target_1_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
7550350	Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995 Oct;11(2):201-3.
7721089	Monteggia LM, Gopalakrishnan M, Touma E, Idler KB, Nash N, Arneric SP, Sullivan JP, Giordano T: Cloning and transient expression of genes encoding the human alpha 4 and beta 2 neuronal nicotinic acetylcholine receptor (nAChR) subunits. Gene. 1995 Apr 3;155(2):189-93.
8833159	Steinlein O, Weiland S, Stoodt J, Propping P: Exon-intron structure of the human neuronal nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4). Genomics. 1996 Mar 1;32(2):289-94.
8906617	Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM: Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 1996 Fall;7(3):217-28.
9009220	Groot Kormelink PJ, Luyten WH: Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32. FEBS Lett. 1997 Jan 6;400(3):309-14.

# Drug_Target_1_HGNC_ID:
HGNC:1958

# Drug_Target_1_HPRD_ID:
00333

# Drug_Target_1_ID:
947

# Drug_Target_1_Locus:
20q13.2-q13.3

# Drug_Target_1_Molecular_Weight:
69958

# Drug_Target_1_Name:
Neuronal acetylcholine receptor subunit alpha-4

# Drug_Target_1_Number_of_Residues:
627

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Nicotine Pathway	SMP00431

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Neuronal acetylcholine receptor subunit alpha-4 precursor
MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISD
VVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWR
PDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFG
SWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIR
RLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTS
LVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKR
PSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGP
SCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEG
GVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSV
SPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDR
IFLWMFIIVCLLGTVGLFLPPWLAGMI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-28

# Drug_Target_1_Specific_Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

# Drug_Target_1_SwissProt_ID:
P43681

# Drug_Target_1_SwissProt_Name:
ACHA4_HUMAN

# Drug_Target_1_Synonyms:
Neuronal acetylcholine receptor subunit alpha-4 precursor

# Drug_Target_1_Theoretical_pI:
7.21

# Drug_Target_1_Transmembrane_Regions:
243-267
275-293
309-330
601-619

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16766716	Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CHRNA7

# Drug_Target_2_GenBank_ID_Gene:
X70297

# Drug_Target_2_GenBank_ID_Protein:
496607

# Drug_Target_2_GeneCard_ID:
CHRNA7

# Drug_Target_2_Gene_Name:
CHRNA7

# Drug_Target_2_Gene_Sequence:
>1509 bp
ATGCGCTGCTCGCCGGGAGGCGTCTGGCTGGGCCTGGCCGCGTCGCTCCTGCACGTGTCC
CTGCAAGGCGAGTTCCAGAGGAAGCTTTACAAGGAGCTGGTCAAGAACTACAATCCCTTG
GAGAGGCCCGTGGCCAATGACTCGCAACCACTCACCGTCTACTTCTCCCTGAGCCTCCTG
CAGATCATGGACGTGGATGAGAAGAACCAAGTTTTAACCACCAACATTTGGCTGCAAATG
TCTTGGACAGATCACTATTTACAGTGGAATGTGTCAGAATATCCAGGGGTGAAGACTGTT
CGTTTCCCAGATGGCCAGATTTGGAAACCAGACATTCTTCTCTATAACAGTGCTGATGAG
CGCTTTGACGCCACATTCCACACTAACGTGTTGGTGAATTCTTCTGGGCATTGCCAGTAC
CTGCCTCCAGGCATATTCAAGAGTTCCTGCTACATCGATGTACGCTGGTTTCCCTTTGAT
GTGCAGCACTGCAAACTGAAGTTTGGGTCCTGGTCTTACGGAGGCTGGTCCTTGGATCTG
CAGATGCAGGAGGCAGATATCAGTGGCTATATCCCCAATGGAGAATGGGACCTAGTGGGA
ATCCCCGGCAAGAGGAGTGAAAGGTTCTATGAGTGCTGCAAAGAGCCCTACCCCGATGTC
ACCTTCACAGTGACCATGCGCCGCAGGACACTCTACTATGGCCTCAACCTGCTGATCCCC
TGTGTGCTCATCTCCGCCCTCGCCCTGCTGGTGTTCCTGCTTCCTGCAGATTCCGGGGAG
AAGATTTCCCTGGGGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCT
GAGATCATGCCCGCAACATCCGATTCGGTACCATTGATAGCCCAGTACTTCGCCAGCACC
ATGATCATCGTGGGCCTCTCGGTGGTGGTGACAGTGATCGTGCTGCAGTACCACCACCAC
GACCCCGACGGGGGCAAGATGCCCAAGTGGACCAGAGTCATCCTTCTGAACTGGTGCGCG
TGGTTCCTGCGAATGAAGAGGCCCGGGGAGGACAAGGTGCGCCCGGCCTGCCAGCACAAG
CAGCGGCGCTGCAGCCTGGCCAGTGTGGAGATGAGCGCCGTGGGCCCGCCGCCCGCCAGC
AACGGGAACCTGCTGTACATCGGCTTCCGCGGCCTGGACGGCGTGCACTGTGTCCCGACC
CCCGACTCTGGGGTAGTGTGTGGCCGCATGGCCTGCTCCCCCACGCACGATGAGCACCTC
CTGCACGGCGGGCAACCCCCCGAGGGGGACCCGGACTTGGCCAAGATCCTGGAGGAGGTC
CGCTACATTGCCAACCGCTTCCGCTGCCAGGACGAAAGCGAGGCGGTCTGCAGCGAGTGG
AAGTTCGCCGCCTGTGTGGTGGACCGCCTGTGCCTCATGGCCTTCTCGGTCTTCACCATC
ATCTGCACCATCGGCATCCTGATGTCGGCTCCCAACTTCGTGGAGGCCGTGTCCAAAGAC
TTTGCGTAA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
11829490	Riley B, Williamson M, Collier D, Wilkie H, Makoff A: A 3-Mb map of a large Segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14. Genomics. 2002 Feb;79(2):197-209.
11840567	Harris RA, Yang A, Stein RC, Lucy K, Brusten L, Herath A, Parekh R, Waterfield MD, O'Hare MJ, Neville MA, Page MJ, Zvelebil MJ: Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics. 2002 Feb;2(2):212-23.
8145738	Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J: Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in Xenopus oocytes. Mol Pharmacol. 1994 Mar;45(3):546-54.
8188270	Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S: Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics. 1994 Jan 15;19(2):379-81.
8906617	Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM: Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 1996 Fall;7(3):217-28.
9009220	Groot Kormelink PJ, Luyten WH: Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32. FEBS Lett. 1997 Jan 6;400(3):309-14.

# Drug_Target_2_HGNC_ID:
HGNC:1960

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4095

# Drug_Target_2_Locus:
15q14

# Drug_Target_2_Molecular_Weight:
56450

# Drug_Target_2_Name:
Neuronal acetylcholine receptor subunit alpha-7

# Drug_Target_2_Number_of_Residues:
502

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_2_Protein_Sequence:
>Neuronal acetylcholine receptor subunit alpha-7
MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQPLTVYFSLSLL
QIMDVDEKNQVLTTNIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADE
RFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSWSYGGWSLDL
QMQEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTLYYGLNLLIP
CVLISALALLVFLLPADSGEKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIAQYFAST
MIIVGLSVVVTVIVLQYHHHDPDGGKMPKWTRVILLNWCAWFLRMKRPGEDKVRPACQHK
QRRCSLASVEMSAVAPPPASNGNLLYIGFRGLDGVHCVPTPDSGVVCGRMACSPTHDEHL
LHGGQPPEGDPDLAKILEEVRYIANRFRCQDESEAVCSEWKFAACVVDRLCLMAFSVFTI
ICTIGILMSAPNFVEAVSKDFA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-22

# Drug_Target_2_Specific_Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

# Drug_Target_2_SwissProt_ID:
P36544

# Drug_Target_2_SwissProt_Name:
ACHA7_HUMAN

# Drug_Target_2_Synonyms:
Neuronal acetylcholine receptor subunit alpha-7 precursor

# Drug_Target_2_Theoretical_pI:
6.44

# Drug_Target_2_Transmembrane_Regions:
231-255
262-280
296-317
470-490

# Drug_Target_3_Cellular_Location:
Cell junction, synapse, postsynaptic cell membrane

# Drug_Target_3_Chromosome_Location:
1

# Drug_Target_3_Drug_References:
16766716	Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M86383

# Drug_Target_3_GenBank_ID_Protein:
177898

# Drug_Target_3_GeneCard_ID:
CHRNA3

# Drug_Target_3_Gene_Name:
CHRNA3

# Drug_Target_3_Gene_Sequence:
>1509 bp
ATGGCTCTGGCCGTCTCGCTGCCCCTGGCCTGTCGCGCGCGGCTGCTGCTGCTGCTGCTG
TCTCTGCTGCCAGTGGCCAGGGCCTCAGAGGCTGAGCACCGTCTATTTGAGCGGCTGTTT
GAAGATTACAATGAGATCATCCGGCCTGTAGCCAACGTGTCTGACCCAGTCATCATCCAT
TTCGAGGTGTCCATGTCTCAGCTGGTGAAGGTGGATGAAGTAAACCAGATCATGGAGACC
AACCTGTGGCTCAAGCAAATCTGGAATGACTACAAGCTGAAGTGGAACCCCTCTGGCTAT
GGTGGGGCAGAGTTCATGCGTGTCCCTGCACAGAAGATCTGGAAGCCAGACATTGTGCTG
TATAACAATGCTGTTGGGGATTTCCAGGTGACGACCAAGACCAAAGCCTTACTCAAGTAC
ACTGGGGAGGTGACTTGGATACCTCCGGCCATCTTTAAGAGCTCCTGTAAAATCGACGTG
ACCTACTTCCCGTTTGATTACCAAAACTGTACCATGAAGTTCGGTTCCTGGTCCTACGAT
AAGGCGAAAATCGATCTGGTCCTGATCGGCTCTTCCATGAACCTCAAGGACTATTGGGAG
AGCGGCGAGTGGGCCATCATCAAAGCCCCAGGCTACAAACACGACATCAAGTACAACTGC
TGCGAGGAGATCTACCCCGACATCACATACTCGCTGTACAGTCGGCGCCTGCCCTTGTTC
TACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTTCCTCACTGTGCTCGTCTTC
TACCTGCCCTCCGACTGCGGTGAGAAGGTGACCCTGTGCATTTCTGTCCTCCTCTCCCTG
ACGGTGTTTCTCCTGGTGATCACTGAGACCATCCCTTCCACCTCGCTGGTCATCCCCCTG
ATTGGAGAGTACCTCCTGTTCACCATGATTTTTGTAACCTTGTCCATCGTCATCACCGTC
TTCGTGCTCAACGTGCACTACAGAACCCCGACGACACACACAATGCCCTCATGGGTGAAG
ACTGTATTCTTGAACCTGCTCCCCAGGGTCATGTTCATGACCAGGCCAACAAGCAACGAG
GGCAACGCTCAGAAGCCGAGGCCCCTCTACGGTGCCGAGCTCTCAAATCTGAATTGCTTC
AGCCGCGCAGAGTCCAAAGGCTGCAAGGAGGGCTACCCCTGCCAGGACGGGATGTGTGGT
TACTGCCACCACCGCAGGATAAAAATCTCCAATTTCAGTGCTAACCTCACGAGAAGCTCT
AGTTCTGAATCTGTTGATGCTGTGGTGTCCCTCTCTGCTTTGTCACCAGAAATCAAAGAA
GCCATCCAAAGTGTCAAGTATATTGCTGAAAATATGAAAGCACAAAATGAAGCCAAAGAG
ATTCAAGATGATTGGAAGTATGTTGCCATGGTGATTGATCGTATTTTTCTGTGGGTTTTC
ACCCTGGTGTGCATTCTAGGGACAGCAGGATTGTTTCTGCAACCCCTGATGGCCAGGGAA
GATGCATAA

# Drug_Target_3_General_Function:
Involved in acetylcholine receptor activity

# Drug_Target_3_General_References:
11450844	Lev-Lehman E, Bercovich D, Xu W, Stockton DW, Beaudet AL: Characterization of the human beta4 nAChR gene and polymorphisms in CHRNA3 and CHRNB4. J Hum Genet. 2001;46(7):362-6.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16572171	Zody MC, Garber M, Sharpe T, Young SK, Rowen L, O'Neill K, Whittaker CA, Kamal M, Chang JL, Cuomo CA, Dewar K, FitzGerald MG, Kodira CD, Madan A, Qin S, Yang X, Abbasi N, Abouelleil A, Arachchi HM, Baradarani L, Birditt B, Bloom S, Bloom T, Borowsky ML, Burke J, Butler J, Cook A, DeArellano K, DeCaprio D, Dorris L 3rd, Dors M, Eichler EE, Engels R, Fahey J, Fleetwood P, Friedman C, Gearin G, Hall JL, Hensley G, Johnson E, Jones C, Kamat A, Kaur A, Locke DP, Madan A, Munson G, Jaffe DB, Lui A, Macdonald P, Mauceli E, Naylor JW, Nesbitt R, Nicol R, O'Leary SB, Ratcliffe A, Rounsley S, She X, Sneddon KM, Stewart S, Sougnez C, Stone SM, Topham K, Vincent D, Wang S, Zimmer AR, Birren BW, Hood L, Lander ES, Nusbaum C: Analysis of the DNA sequence and duplication history of human chromosome 15. Nature. 2006 Mar 30;440(7084):671-5.
1989896	Mihovilovic M, Roses AD: Expression of mRNAs in human thymus coding for the alpha 3 subunit of a neuronal acetylcholine receptor. Exp Neurol. 1991 Feb;111(2):175-80.
2336208	Fornasari D, Chini B, Tarroni P, Clementi F: Molecular cloning of human neuronal nicotinic receptor alpha 3-subunit. Neurosci Lett. 1990 Apr 6;111(3):351-6.
8906617	Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM: Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 1996 Fall;7(3):217-28.
9009220	Groot Kormelink PJ, Luyten WH: Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32. FEBS Lett. 1997 Jan 6;400(3):309-14.
9921897	Rempel N, Heyers S, Engels H, Sleegers E, Steinlein OK: The structures of the human neuronal nicotinic acetylcholine receptor beta2- and alpha3-subunit genes (CHRNB2 and CHRNA3). Hum Genet. 1998 Dec;103(6):645-53.

# Drug_Target_3_HGNC_ID:
GNC:1957

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6079

# Drug_Target_3_Locus:
15q24

# Drug_Target_3_Molecular_Weight:
57479.5

# Drug_Target_3_Name:
Neuronal acetylcholine receptor subunit alpha-3

# Drug_Target_3_Number_of_Residues:
505

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Nicotine Pathway	SMP00431

# Drug_Target_3_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_3_Protein_Sequence:
>Neuronal acetylcholine receptor subunit alpha-3
MGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEIIRPVANVSDPV
IIHFEVSMSQLVKVDEVNQIMETNLWLKQIWNDYKLKWNPSDYGGAEFMRVPAQKIWKPD
IVLYNNAVGDFQVDDKTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSW
SYDKAKIDLVLIGSSMNLKDYWESGEWAIIKAPGYKHDIKYNCCEEIYPDITYSLYIRRL
PLFYTINLIIPCLLISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLV
IPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTTHTMPSWVKTVFLNLLPRVMFMTRPT
SNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGMCGYCHHRRIKISNFSANLT
RSSSSESVDAVLSLSALSPEIKEAIQSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFL
WVFTLVCILGTAGLFLQPLMAREDA

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-31

# Drug_Target_3_Specific_Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

# Drug_Target_3_SwissProt_ID:
P32297

# Drug_Target_3_SwissProt_Name:
ACHA3_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
6.40

# Drug_Target_3_Transmembrane_Regions:
241-265
273-291
307-328
478-497

# Drug_Target_4_Cellular_Location:
Cell junction, synapse, postsynaptic cell membrane

# Drug_Target_4_Chromosome_Location:
8

# Drug_Target_4_Drug_References:
16766716	Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
U62435

# Drug_Target_4_GenBank_ID_Protein:
1458118

# Drug_Target_4_GeneCard_ID:
CHRNA6

# Drug_Target_4_Gene_Name:
CHRNA6

# Drug_Target_4_Gene_Sequence:
>1485 bp
ATGCTGACCAGCAAGGGGCAGGGATTCCTTCATGGGGGCTTGTGTCTCTGGCTGTGTGTG
TTCACACCTTTCTTTAAAGGCTGTGTGGGCTGTGCAACTGAGGAGAGGCTCTTCCACAAA
CTGTTTTCTCATTACAACCAGTTCATCAGGCCTGTGGAAAACGTTTCCGACCCTGTCACG
GTACACTTTGAAGTGGCCATCACCCAGCTGGCCAACGTGGATGAAGTAAACCAGATCATG
GAAACCAATTTGTGGCTGCGTCACATCTGGAATGATTATAAATTGCGCTGGGATCCAATG
GAATATGATGGCATTGAGACTCTTCGCGTTCCTGCAGATAAGATTTGGAAGCCCGACATT
GTTCTCTATAACAATGCTGTTGGTGACTTCCAAGTAGAAGGCAAAACAAAAGCTCTTCTT
AAATACAATGGCATGATAACCTGGACTCCACCAGCTATTTTTAAGAGTTCCTGCCCTATG
GATATCACCTTTTTCCCTTTTGATCATCAAAACTGTTCCCTAAAATTTGGTTCCTGGACG
TATGACAAAGCTGAAATTGATCTTCTAATCATTGGATCAAAAGTGGATATGAATGATTTT
TGGGAAAACAGTGAATGGGAAATCATTGATGCCTCTGGCTACAAACATGACATCAAATAC
AACTGTTGTGAAGAGATATACACAGATATAACCTATTCTTTCTACATTAGAAGATTGCCG
ATGTTTTACACGATTAATCTGATCATCCCTTGTCTCTTTATTTCATTTCTAACCGTGTTG
GTCTTTTACCTTCCTTCGGACTGTGGTGAAAAAGTGACGCTTTGTATTTCAGTCCTGCTT
TCTCTGACTGTGTTTTTGCTGGTCATCACAGAAACCATCCCATCCACATCTCTGGTGGTC
CCACTGGTGGGTGAGTACCTGCTGTTCACCATGATCTTTGTCACACTGTCCATCGTGGTG
ACTGTGTTTGTGTTGAACATACACTACCGCACCCCAACCACGCACACAATGCCCAGGTGG
GTGAAGACAGTTTTCCTGAAGCTGCTGCCCCAGGTCCTGCTGATGAGGTGGCCTCTGGAC
AAGACAAGGGGCACAGGCTCTGATGCAGTGCCCAGAGGCCTTGCCAGGAGGCCTGCCAAA
GGCAAGCTTGCAAGCCATGGGGAACCCAGACATCTTAAAGAATGCTTCCATTGTCACAAA
TCAAATGAGCTTGCCACAAGCAAGAGAAGATTAAGTCATCAGCCATTACAGTGGGTGGTG
GAAAATTCGGAGCACTCGCCTGAAGTTGAAGATGTGATTAACAGTGTTCAGTTCATAGCA
GAAAACATGAAGAGCCACAATGAAACCAAGGAGGTAGAAGATGACTGGAAATACGTGGCC
ATGGTGGTGGACAGAGTATTTCTTTGGGTATTTATAATTGTCTGTGTATTTGGAACTGCA
GGGCTATTTCTACAGCCACTACTTGGGAACACAGGAAAATCTTAA

# Drug_Target_4_General_Function:
Involved in acetylcholine receptor activity

# Drug_Target_4_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17081983	Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.
8906617	Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM: Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci. 1996 Fall;7(3):217-28.

# Drug_Target_4_HGNC_ID:
GNC:15963

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6081

# Drug_Target_4_Locus:
8p11.21

# Drug_Target_4_Molecular_Weight:
56897.7

# Drug_Target_4_Name:
Neuronal acetylcholine receptor subunit alpha-6

# Drug_Target_4_Number_of_Residues:
494

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_4_Protein_Sequence:
>Neuronal acetylcholine receptor subunit alpha-6
MLTSKGQGFLHGGLCLWLCVFTPFFKGCVGCATEERLFHKLFSHYNQFIRPVENVSDPVT
VHFEVAITQLANVDEVNQIMETNLWLRHIWNDYKLRWDPMEYDGIETLRVPADKIWKPDI
VLYNNAVGDFQVEGKTKALLKYNGMITWTPPAIFKSSCPMDITFFPFDHQNCSLKFGSWT
YDKAEIDLLIIGSKVDMNDFWENSEWEIIDASGYKHDIKYNCCEEIYTDITYSFYIRRLP
MFYTINLIIPCLFISFLTVLVFYLPSDCGEKVTLCISVLLSLTVFLLVITETIPSTSLVV
PLVGEYLLFTMIFVTLSIVVTVFVLNIHYRTPTTHTMPRWVKTVFLKLLPQVLLMRWPLD
KTRGTGSDAVPRGLARRPAKGKLASHGEPRHLKECFHCHKSNELATSKRRLSHQPLQWVV
ENSEHSPEVEDVINSVQFIAENMKSHNETKEVEDDWKYVAMVVDRVFLWVFIIVCVFGTA
GLFLQPLLGNTGKS

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-25

# Drug_Target_4_Specific_Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

# Drug_Target_4_SwissProt_ID:
Q15825

# Drug_Target_4_SwissProt_Name:
ACHA6_HUMAN

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
6.60

# Drug_Target_4_Transmembrane_Regions:
240-264
272-290
306-327
466-484

#END_DRUGCARD DB01273
